Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
NCT ID NCT06809530
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two immune checkpoints (PD-1 and CTLA-4), and pemetrexed, a chemotherapy agent. The study aims to find the safest dose and evaluate how well the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a bispecific antibody targeting PD-1 and CTLA-4 (QL1706) combined with pemetrexed, both given via spinal injection
- What this could lead to
- If successful, this could offer a new treatment option for people with leptomeningeal metastasis, a serious complication of cancer that spreads to the lining of the brain and spinal cord.
- What could go wrong
- This is an early-phase trial with only 34 participants, so results may not apply broadly. The combination therapy carries risks of severe neurological side effects, such as chemical meningitis.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTLA4 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine
Beijing, Beijing Municipality, China
-
Beijing Chest Hospital, Capital Medical University
Beijing, 101100, China
-
Huizhou First Hospital Affiliated to Guangdong Medical University
Huizhou, Guangdong, China
-
The Affiliated Huizhou Hospital, Guangzhou Medical University
Huizhou, Guangdong, 516000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a new infusion drug tame advanced solid tumors?
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can a new drug shrink Hard-to-Treat solid tumors?